Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.

Eur J Pharm Biopharm. 2019 Sep;142:543-552. doi: 10.1016/j.ejpb.2019.08.004. Epub 2019 Aug 6.

PMID:
31398437
2.

Structure and Function of the Branched Receptor-Binding Complex of Bacteriophage CBA120.

Plattner M, Shneider MM, Arbatsky NP, Shashkov AS, Chizhov AO, Nazarov S, Prokhorov NS, Taylor NMI, Buth SA, Gambino M, Gencay YE, Brøndsted L, Kutter EM, Knirel YA, Leiman PG.

J Mol Biol. 2019 Sep 6;431(19):3718-3739. doi: 10.1016/j.jmb.2019.07.022. Epub 2019 Jul 17.

PMID:
31325442
3.

Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.

Chang RYK, Das T, Manos J, Kutter E, Morales S, Chan HK.

AAPS J. 2019 Apr 4;21(3):49. doi: 10.1208/s12248-019-0315-0.

PMID:
30949776
4.

Storage stability of inhalable phage powders containing lactose at ambient conditions.

Chang RYK, Wallin M, Kutter E, Morales S, Britton W, Li J, Chan HK.

Int J Pharm. 2019 Apr 5;560:11-18. doi: 10.1016/j.ijpharm.2019.01.050. Epub 2019 Jan 31.

PMID:
30710661
5.

Jet nebulization of bacteriophages with different tail morphologies - Structural effects.

Leung SSY, Carrigy NB, Vehring R, Finlay WH, Morales S, Carter EA, Britton WJ, Kutter E, Chan HK.

Int J Pharm. 2019 Jan 10;554:322-326. doi: 10.1016/j.ijpharm.2018.11.026. Epub 2018 Nov 13.

PMID:
30445174
6.

Resolving Digital Staphylococcal Osteomyelitis Using Bacteriophage-A Case Report.

Fish R, Kutter E, Bryan D, Wheat G, Kuhl S.

Antibiotics (Basel). 2018 Oct 2;7(4). pii: E87. doi: 10.3390/antibiotics7040087.

7.

Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.

Rohde C, Wittmann J, Kutter E.

Surg Infect (Larchmt). 2018 Nov/Dec;19(8):737-744. doi: 10.1089/sur.2018.184. Epub 2018 Oct 9. Review.

8.

Single Neurons in the Human Brain Encode Numbers.

Kutter EF, Bostroem J, Elger CE, Mormann F, Nieder A.

Neuron. 2018 Nov 7;100(3):753-761.e4. doi: 10.1016/j.neuron.2018.08.036. Epub 2018 Sep 20.

PMID:
30244883
9.

Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.

Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan HK.

Int J Pharm. 2018 Nov 15;551(1-2):158-165. doi: 10.1016/j.ijpharm.2018.09.024. Epub 2018 Sep 14.

PMID:
30223075
10.

From Host to Phage Metabolism: Hot Tales of Phage T4's Takeover of E. coli.

Kutter E, Bryan D, Ray G, Brewster E, Blasdel B, Guttman B.

Viruses. 2018 Jul 21;10(7). pii: E387. doi: 10.3390/v10070387. Review.

11.

Microfluidic-assisted bacteriophage encapsulation into liposomes.

Leung SSY, Morales S, Britton W, Kutter E, Chan HK.

Int J Pharm. 2018 Jul 10;545(1-2):176-182. doi: 10.1016/j.ijpharm.2018.04.063. Epub 2018 May 2.

PMID:
29729404
12.

Effect of storage temperature on the stability of spray dried bacteriophage powders.

Leung SSY, Parumasivam T, Nguyen A, Gengenbach T, Carter EA, Carrigy NB, Wang H, Vehring R, Finlay WH, Morales S, Britton WJ, Kutter E, Chan HK.

Eur J Pharm Biopharm. 2018 Jun;127:213-222. doi: 10.1016/j.ejpb.2018.02.033. Epub 2018 Feb 24.

13.

Nebulization effects on structural stability of bacteriophage PEV 44.

Astudillo A, Leung SSY, Kutter E, Morales S, Chan HK.

Eur J Pharm Biopharm. 2018 Apr;125:124-130. doi: 10.1016/j.ejpb.2018.01.010. Epub 2018 Jan 17.

PMID:
29353018
14.

Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.

Chang RYK, Chen K, Wang J, Wallin M, Britton W, Morales S, Kutter E, Li J, Chan HK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01714-17. doi: 10.1128/AAC.01714-17. Print 2018 Feb.

15.

Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials.

Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S.

Methods Mol Biol. 2018;1693:159-170. doi: 10.1007/978-1-4939-7395-8_14.

PMID:
29119440
16.

Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.

Chang RY, Wong J, Mathai A, Morales S, Kutter E, Britton W, Li J, Chan HK.

Eur J Pharm Biopharm. 2017 Dec;121:1-13. doi: 10.1016/j.ejpb.2017.09.002. Epub 2017 Sep 7.

17.

An online adaptive screening procedure for selective neuronal responses.

Knieling S, Niediek J, Kutter E, Bostroem J, Elger CE, Mormann F.

J Neurosci Methods. 2017 Nov 1;291:36-42. doi: 10.1016/j.jneumeth.2017.08.002. Epub 2017 Aug 4.

PMID:
28826654
18.

Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders.

Leung SSY, Parumasivam T, Gao FG, Carter EA, Carrigy NB, Vehring R, Finlay WH, Morales S, Britton WJ, Kutter E, Chan HK.

Int J Pharm. 2017 Apr 15;521(1-2):141-149. doi: 10.1016/j.ijpharm.2017.01.060. Epub 2017 Feb 3.

19.

Bacteriophage T4 Infection of Stationary Phase E. coli: Life after Log from a Phage Perspective.

Bryan D, El-Shibiny A, Hobbs Z, Porter J, Kutter EM.

Front Microbiol. 2016 Sep 8;7:1391. doi: 10.3389/fmicb.2016.01391. eCollection 2016.

20.

Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Leung SS, Parumasivam T, Gao FG, Carrigy NB, Vehring R, Finlay WH, Morales S, Britton WJ, Kutter E, Chan HK.

Pharm Res. 2016 Jun;33(6):1486-96. doi: 10.1007/s11095-016-1892-6. Epub 2016 Feb 29.

21.

What Can We Learn from a Metagenomic Analysis of a Georgian Bacteriophage Cocktail?

Zschach H, Joensen KG, Lindhard B, Lund O, Goderdzishvili M, Chkonia I, Jgenti G, Kvatadze N, Alavidze Z, Kutter EM, Hasman H, Larsen MV.

Viruses. 2015 Dec 12;7(12):6570-89. doi: 10.3390/v7122958.

22.

Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model Assays.

Holguín AV, Rangel G, Clavijo V, Prada C, Mantilla M, Gomez MC, Kutter E, Taylor C, Fineran PC, Barrios AF, Vives MJ.

Viruses. 2015 Aug 12;7(8):4602-23. doi: 10.3390/v7082835.

23.

Re-establishing a place for phage therapy in western medicine.

Kutter EM, Kuhl SJ, Abedon ST.

Future Microbiol. 2015;10(5):685-8. doi: 10.2217/fmb.15.28. Review. No abstract available.

24.

Quality and safety requirements for sustainable phage therapy products.

Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G.

Pharm Res. 2015 Jul;32(7):2173-9. doi: 10.1007/s11095-014-1617-7. Epub 2015 Jan 14.

25.

Rubber hand illusion affects joint angle perception.

Butz MV, Kutter EF, Lorenz C.

PLoS One. 2014 Mar 26;9(3):e92854. doi: 10.1371/journal.pone.0092854. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e102852.

26.

Anna S. Tikhonenko: Electron microscopist extraordinary.

Popenko VI, Kutter EM, Ackermann HW.

Bacteriophage. 2013 Jan 1;3(1):e23646.

27.

The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.

Essoh C, Blouin Y, Loukou G, Cablanmian A, Lathro S, Kutter E, Thien HV, Vergnaud G, Pourcel C.

PLoS One. 2013 Apr 24;8(4):e60575. doi: 10.1371/journal.pone.0060575. Print 2013.

28.

A suggested new bacteriophage genus: "Viunalikevirus".

Adriaenssens EM, Ackermann HW, Anany H, Blasdel B, Connerton IF, Goulding D, Griffiths MW, Hooton SP, Kutter EM, Kropinski AM, Lee JH, Maes M, Pickard D, Ryu S, Sepehrizadeh Z, Shahrbabak SS, Toribio AL, Lavigne R.

Arch Virol. 2012 Oct;157(10):2035-46. Epub 2012 Jun 17.

29.

Phage treatment of human infections.

Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM.

Bacteriophage. 2011 Mar;1(2):66-85.

30.

Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI.

Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Review.

31.

Characterization of a ViI-like phage specific to Escherichia coli O157:H7.

Kutter EM, Skutt-Kakaria K, Blasdel B, El-Shibiny A, Castano A, Bryan D, Kropinski AM, Villegas A, Ackermann HW, Toribio AL, Pickard D, Anany H, Callaway T, Brabban AD.

Virol J. 2011 Sep 7;8:430. doi: 10.1186/1743-422X-8-430.

32.

Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157:H7 levels in sheep guts.

Raya RR, Oot RA, Moore-Maley B, Wieland S, Callaway TR, Kutter EM, Brabban AD.

Bacteriophage. 2011 Jan;1(1):15-24.

33.

Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens.

Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T, Adamia R, Topuria T, Kutter E, Rohde C, Kutateladze M.

Microb Biotechnol. 2011 Sep;4(5):643-50. doi: 10.1111/j.1751-7915.2011.00259.x. Epub 2011 Apr 11.

34.

The phage therapy paradigm: prêt-à-porter or sur-mesure?

Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R.

Pharm Res. 2011 Apr;28(4):934-7. doi: 10.1007/s11095-010-0313-5. Epub 2010 Nov 10. No abstract available.

PMID:
21063753
35.

Molecular and physiological analysis of three Pseudomonas aeruginosa phages belonging to the "N4-like viruses".

Ceyssens PJ, Brabban A, Rogge L, Lewis MS, Pickard D, Goulding D, Dougan G, Noben JP, Kropinski A, Kutter E, Lavigne R.

Virology. 2010 Sep 15;405(1):26-30. doi: 10.1016/j.virol.2010.06.011.

36.

Occurrence of Salmonella-specific bacteriophages in swine feces collected from commercial farms.

Callaway TR, Edrington TS, Brabban A, Kutter E, Karriker L, Stahl C, Wagstrom E, Anderson RC, Genovese K, McReynolds J, Harvey R, Nisbet DJ.

Foodborne Pathog Dis. 2010 Jul;7(7):851-6. doi: 10.1089/fpd.2009.0512.

PMID:
20230290
37.

Phage therapy in clinical practice: treatment of human infections.

Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST.

Curr Pharm Biotechnol. 2010 Jan;11(1):69-86. Review.

PMID:
20214609
38.

Phage host range and efficiency of plating.

Kutter E.

Methods Mol Biol. 2009;501:141-9. doi: 10.1007/978-1-60327-164-6_14.

PMID:
19066818
39.

Bacteriophage isolated from feedlot cattle can reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts.

Callaway TR, Edrington TS, Brabban AD, Anderson RC, Rossman ML, Engler MJ, Carr MA, Genovese KJ, Keen JE, Looper ML, Kutter EM, Nisbet DJ.

Foodborne Pathog Dis. 2008 Apr;5(2):183-91. doi: 10.1089/fpd.2007.0057.

PMID:
18407757
40.

Prevalence of Escherichia coli O157 and O157:H7-infecting bacteriophages in feedlot cattle feces.

Oot RA, Raya RR, Callaway TR, Edrington TS, Kutter EM, Brabban AD.

Lett Appl Microbiol. 2007 Oct;45(4):445-53.

41.

Fecal prevalence of Escherichia coli O157, Salmonella, Listeria, and Bacteriophage Infecting E. coli O157:H7 in feedlot cattle in the Southern Plains region of the United States.

Callaway TR, Edrington TS, Brabban AD, Keen JE, Anderson RC, Rossman ML, Engler MJ, Genovese KJ, Gwartney BL, Reagan JO, Poole TL, Harvey RB, Kutter EM, Nisbet DJ.

Foodborne Pathog Dis. 2006 Fall;3(3):234-44.

PMID:
16972771
42.

Isolation and characterization of a new T-even bacteriophage, CEV1, and determination of its potential to reduce Escherichia coli O157:H7 levels in sheep.

Raya RR, Varey P, Oot RA, Dyen MR, Callaway TR, Edrington TS, Kutter EM, Brabban AD.

Appl Environ Microbiol. 2006 Sep;72(9):6405-10.

43.

Anecdotal, historical and critical commentaries on genetics. Gisela Mosig.

Nossal NG, Franklin JL, Kutter E, Drake JW.

Genetics. 2004 Nov;168(3):1097-104. No abstract available.

44.

Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh.

Chibani-Chennoufi S, Sidoti J, Bruttin A, Dillmann ML, Kutter E, Qadri F, Sarker SA, Brüssow H.

J Bacteriol. 2004 Dec;186(24):8287-94.

45.

In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy.

Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H.

Antimicrob Agents Chemother. 2004 Jul;48(7):2558-69.

46.

Bacteriophage T4 genome.

Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Rüger W.

Microbiol Mol Biol Rev. 2003 Mar;67(1):86-156, table of contents. Review.

47.

Effects of the antibiotic ionophores monensin, lasalocid, laidlomycin propionate and bambermycin on Salmonella and E. coli O157:H7 in vitro.

Edrington TS, Callaway TR, Varey PD, Jung YS, Bischoff KM, Elder RO, Anderson RC, Kutter E, Brabban AD, Nisbet DJ.

J Appl Microbiol. 2003;94(2):207-13.

48.

Comparison of synonymous codon distribution patterns of bacteriophage and host genomes.

Kunisawa T, Kanaya S, Kutter E.

DNA Res. 1998 Dec 31;5(6):319-26.

PMID:
10048480
49.

The roles of the bacteriophage T4 r genes in lysis inhibition and fine-structure genetics: a new perspective.

Paddison P, Abedon ST, Dressman HK, Gailbreath K, Tracy J, Mosser E, Neitzel J, Guttman B, Kutter E.

Genetics. 1998 Apr;148(4):1539-50.

50.

Evolution of T4-related phages.

Kutter E, Gachechiladze K, Poglazov A, Marusich E, Shneider M, Aronsson P, Napuli A, Porter D, Mesyanzhinov V.

Virus Genes. 1995;11(2-3):285-97. Review.

PMID:
8828153

Supplemental Content

Loading ...
Support Center